Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients.

Aim: To describe factors associated with treatment failure and frequency of resistance-associated substitutions (RAS).

Methods: Human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfected patients starting a first direct-acting antiviral (DAA) regimen before February 2016 and included in the French ANRS CO13 HEPAVIH cohort were eligible. Failure was defined as: (1) non-response [HCV-RNA remained detectable during treatment, at end of treatment (EOT)]; and (2) relapse (HCV-RNA suppressed at EOT but detectable thereafter).